CDK4/6 inhibition uncovers subtype-specific vulnerabilities and immune-related responses in esophageal squamous cell carcinoma

Fabiana Moresi, Diego Japón-Ruiz, Matteo Serra, Marta Ávalos-Moreno, Eloine Garcia, Katia Coulonval, Andrea Pavesi, Benjamin Beck, Xavier Bisteau · 2026

Read CDK4/6 inhibition uncovers subtype-specific vulnerabilities and immune-related responses in esophageal squamous cell carcinoma by Fabiana Moresi, Diego Japón-Ruiz, Matteo Serra, Marta Ávalos-Moreno, Eloine Garcia, Katia Coulonval, Andrea Pavesi, Benjamin Beck, Xavier Bisteau (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13424112.txt.

Description

Fabiana Moresi and colleagues tested palbociclib as first-line therapy in 2026 across 22 esophageal squamous cancer cell lines, a disease with few good options. CDK4/6 blockers had shown little benefit as second-line drugs, yet their first-line, subtype-specific effects were uncharted.

Cell lines split into resistant, delayed, and arrested responders tied to Rb-pathway status, and delayed responders accumulated DNA damage that triggered interferon genes and drew immune cells into tumor spheroids. The paper nominates early palbociclib for molecularly defined esophageal cancer, pairing growth arrest with immune recruitment in molecularly defined subtypes.

Catalog record

CREATORFabiana Moresi, Diego Japón-Ruiz, Matteo Serra, Marta Ávalos-Moreno, Eloine Garcia, Katia Coulonval, Andrea Pavesi, Benjamin Beck, Xavier Bisteau
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE77 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13424112

Browse the full library · About the Tower of Babel